A Phase III, Multicenter, Randomized, Open Study of SHR3680 Compared to Bicalutamide in the Treatment of Patients With Hormone Sensitive Prostate Cancer
Phase of Trial: Phase III
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs SHR 3680 (Primary) ; Bicalutamide
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 22 Aug 2018 Status changed from not yet recruiting to recruiting.
- 14 May 2018 Planned initiation date changed from 30 Apr 2018 to 30 May 2018.
- 11 May 2018 New trial record